Alumis Inc. ALMS
We take great care to ensure that the data presented and summarized in this overview for ALUMIS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ALMS
Top Purchases
Top Sells
About ALMS
Insider Transactions at ALMS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 29
2025
|
Mark Christopher Bradley Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,750
+35.44%
|
-
|
|
Jul 29
2025
|
Jorn Drappa Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,450
+47.22%
|
-
|
|
Jul 29
2025
|
David M Goldstein Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+48.12%
|
-
|
|
Jul 29
2025
|
Roy C. Hardiman Chief Business & Strategy Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+11.95%
|
-
|
|
Jul 29
2025
|
John R. Schroer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+50.0%
|
-
|
|
Jul 29
2025
|
Derrick Richardson SVP, People and Culture |
BUY
Grant, award, or other acquisition
|
Direct |
42,800
+50.0%
|
-
|
|
Jul 29
2025
|
Sanam Pangali Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+47.37%
|
-
|
|
May 21
2025
|
Srinivas Akkaraju |
BUY
Grant, award, or other acquisition
|
Indirect |
1,214,582
+20.19%
|
-
|
|
May 21
2025
|
Ayur Maya Capital Management Company, LP Director |
BUY
Grant, award, or other acquisition
|
Indirect |
4,493,741
+22.89%
|
-
|
|
May 21
2025
|
Patrick Machado |
BUY
Grant, award, or other acquisition
|
Indirect |
7,064
+50.0%
|
-
|
|
May 06
2025
|
Foresite Capital Management Vi LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.47%
|
$80,000
$4.34 P/Share
|
|
May 06
2025
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.47%
|
$80,000
$4.34 P/Share
|
|
May 06
2025
|
James B. Tananbaum Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.47%
|
$80,000
$4.34 P/Share
|
|
May 05
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
160,370
+2.17%
|
$641,480
$4.93 P/Share
|
|
May 02
2025
|
Foresite Capital Management Vi LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.59%
|
$100,000
$4.62 P/Share
|
|
May 02
2025
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.59%
|
$100,000
$4.62 P/Share
|
|
May 02
2025
|
James B. Tananbaum Director |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.59%
|
$100,000
$4.62 P/Share
|
|
May 02
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
159,920
+4.46%
|
$639,680
$4.55 P/Share
|
|
Apr 02
2025
|
Alan Colowick |
BUY
Open market or private purchase
|
Indirect |
2,300
+11.11%
|
$16,100
$7.49 P/Share
|
|
Apr 01
2025
|
Martin Babler President, CEO and Chairman |
BUY
Open market or private purchase
|
Indirect |
15,650
+12.82%
|
$93,900
$6.44 P/Share
|
Last 12 Months Summary
Buy / Acquisition
6.39M
Shares
From
16
Insiders
| Grant, award, or other acquisition | 5.9M shares |
|---|---|
| Open market or private purchase | 489K shares |
Sell / Disposition
0
Shares
From
0
Insiders